Aviir pumps up with $1M for heart diagnostics

Aviir, the Palo Alto, Calif. company that turned Stanford research into technology used to diagnose heart conditions, has brought in $1 million in equity, debt, rights and securities, according to a filing with the SEC. It adds this amount to $1 million raised in August and $7.8 million in bridge financing secured in January from Aberdare Ventures, Bay City Capital and New Leaf Venture Partners. Before that it raised funds in March 2008 amounting to… Continue Reading

Aviir pumps in $7.8M for heart diagnostics

Stealthy biotech firm Aviir just raised a $7.8 million bridge round of financing to last it through the rest of 2009, according to VentureWire. Based in Palo Alto, Calif., the company hasn’t released much information about its actual products — only that its methods may eventually be used to detect early warning signs of heart disease, heart attacks or strokes on the molecular level.

Born out of research conducted in Stanford University labs, the technology will… Continue Reading

Life-science briefing: Wednesday, March 26, 2008

Life-science briefing: Wednesday, March 26, 2008

TODAY’S HEADLINES:

OptiMedica takes in $16M for eye-treatment lasers (release)
Genome analyzer BioNanomatrix raises $5M (release)
Heart diagnostic startup Aviir gets another $1.5M (VBLS exclusive)
Pharmaca, integrative-pharmacy chain, draws $20M (release)
LifeWatch, cardiac-monitoring device maker, withdraws IPO (IPOhome)
Jerry DeVries, Steven Whitlock join PTV Sciences as venture partners (VentureWire)

OptiMedica takes in $16M for eye-treatment lasers – OptiMedica, a Santa Clara, Calif., medical-device maker, raised $16 million in a third funding round. Investors included Kleiner Perkins Caufield & Byers, Alloy Ventures and… Continue Reading

Life sciences briefing: Wednesday, Oct. 3, 2007

Life sciences briefing: Wednesday, Oct. 3, 2007

Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics

Heart-diagnostic maker Aviir raises $11.3M — Palo Alto, Calif.-based Aviir, a biotech developing cardiovascular diagnostics based on Stanford research, raised $11.3 million of an expected $25 million second funding round, PE Hub reports. The news is presumably from one of those paper-based SEC filings that are supposed to be digitized before long.

Investors include Bay City Capital, Aberdare Ventures and New Leaf Ventures. Aviir hasn’t said much about its technology… Continue Reading